Author: Blanco-Melo, Daniel; Nilsson-Payant, Benjamin E.; Liu, Wen-Chun; Uhl, Skyler; Hoagland, Daisy; Møller, Rasmus; Jordan, Tristan X.; Oishi, Kohei; Panis, Maryline; Sachs, David; Wang, Taia T.; Schwartz, Robert E.; Lim, Jean K.; Albrecht, Randy A.; tenOever, Benjamin R.
Title: Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Cord-id: pcekcvwr Document date: 2020_5_15
ID: pcekcvwr
Snippet: Viral pandemics, such as the one caused by SARS-CoV-2, pose an imminent threat to humanity. Because of its recent emergence, there is a paucity of information regarding viral behavior and host response following SARS-CoV-2 infection. Here we offer an in-depth analysis of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses. Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a
Document: Viral pandemics, such as the one caused by SARS-CoV-2, pose an imminent threat to humanity. Because of its recent emergence, there is a paucity of information regarding viral behavior and host response following SARS-CoV-2 infection. Here we offer an in-depth analysis of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses. Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response. This response is defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6. We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19.
Search related documents:
Co phrase search for related documents- abnormally high and acute respiratory distress syndrome: 1, 2, 3
- abnormally high and adaptive immune response: 1
- activation receptor and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- activation receptor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activation receptor and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- activation receptor and adaptive immune response: 1, 2, 3, 4, 5, 6
- activation receptor and adaptive immune response activation: 1, 2
- activation receptor and low expression: 1, 2
- acute lung injury and adaptive immune response: 1, 2, 3, 4, 5
- acute lung injury and longitudinal study: 1
- acute lung injury and low expression: 1, 2
- acute respiratory and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and adaptive immune response activation: 1, 2, 3, 4, 5
- acute respiratory and additional research: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and additional sampling: 1, 2, 3, 4
- acute respiratory and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and low expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and low ifn expression: 1, 2, 3
- acute respiratory and low moi infection: 1
Co phrase search for related documents, hyperlinks ordered by date